Landmark Trial: Preventative KRAS Vaccine Elicits Durable Immune Response in High-Risk Pancreatic Cancer Patients

The paradigm of treating pancreatic cancer is shifting from late-stage salvage to early interception. For decades, pancreatic ductal adenocarcinoma (PDAC) has remained one of the deadliest human malignancies, largely because it is diagnosed long after it has spread beyond the pancreas.[1][2]

But PDAC does not appear overnight. The disease typically stews for a decade or more as microscopic precursor lesions—often visible on scans as small cysts—slowly acquire genetic mutations. This long runway presents a theoretical window to stop the cancer before it truly begins.[3][4]

Now, a landmark Phase 1 clinical trial published in Cancer Discovery has provided the first human evidence that an off-the-shelf vaccine can train the immune system to recognize and attack these precancerous cells.[1][3]

The trial, led by researchers at the Johns Hopkins Kimmel Cancer Center, tested an investigational peptide vaccine known as mKRAS-VAX. The vaccine is designed to target the KRAS gene, a notorious oncogene whose mutated forms act as the primary biological engine in more than 90% of pancreatic cancers.[2][4]

Historically, mutated KRAS was considered "undruggable" due to its smooth molecular structure. Rather than trying to block the protein with a chemical drug, the mKRAS-VAX approach uses small synthetic fragments of the mutated protein to teach the patient's T-cells what the enemy looks like.[2][6]

The study enrolled 20 individuals who were living in the agonizing limbo of high pancreatic cancer risk. These participants either possessed a hereditary genetic predisposition—such as BRCA or PALB2 mutations—or had radiographic evidence of concerning pancreatic cysts, known as intraductal papillary mucinous neoplasms (IPMNs).[1][6]

Under the current standard of care, these high-risk patients undergo relentless surveillance imaging. If a cyst begins to look suspicious, the only preventative option is a massive, life-altering surgical resection. The psychological toll of this "watch and wait" protocol is immense.[3][7]

Participants in the trial received the mKRAS-VAX alongside an immune-boosting adjuvant called poly-ICLC. The regimen consisted of a prime-boost schedule: subcutaneous injections at weeks one, three, and five, followed by a final booster dose at week 13.[1][2]

The primary objective of the Phase 1 trial was to establish safety, and the results were highly encouraging. The vaccine was well-tolerated across the cohort, with researchers reporting only mild to moderate grade 1 and 2 adverse events, such as localized injection site soreness.[1][4]

But the secondary objective—measuring the immune system's response—delivered the breakthrough. Blood analyses revealed that 90% of the participants (18 out of 20) developed a significant, mutant-KRAS-specific T-cell response.[2][3]

The magnitude of the response was substantial. Participants experienced a median 18.2-fold increase in targeted T-cells, successfully generating both CD4-positive helper cells and CD8-positive killer cells equipped to hunt the KRAS mutation.[2][7]

Crucially, this immune activation was not a fleeting reaction. Longitudinal sequencing demonstrated that the vaccine-induced memory T-cells remained detectable in the patients' peripheral blood for up to two years after the final injection.[1][5]

"This long-lasting response is particularly noteworthy when assessing for possible interception of cancer, which requires long-lasting immunity," noted Dr. Neeha Zaidi, an associate professor of oncology at Johns Hopkins and co-senior author of the study.[3][5]

While the trial was not large enough to definitively prove that the vaccine prevents cancer, the early clinical signals are unprecedented. After a median follow-up of 16.5 months, not a single vaccinated participant had developed pancreatic cancer or required surgical removal of a high-risk lesion.[2][4]

Furthermore, researchers observed a tangible impact on the precursor lesions themselves. Among the vaccinated cohort, 37.5% experienced a radiographic reduction or complete resolution of their pancreatic cysts.[5][7]

By comparison, when researchers looked at a similar cohort of unvaccinated high-risk patients, only 6.8% experienced spontaneous cyst reduction. This stark contrast suggests the vaccine-induced T-cells are actively clearing precancerous tissue.[5]

Despite the optimism, the research team and independent oncologists emphasize transparent uncertainty. A 20-person Phase 1 trial is fundamentally a proof-of-concept; it is not powered to confirm long-term clinical efficacy.[1][7]

One major open question is tissue infiltration. While the trial proved that KRAS-hunting T-cells are circulating in the blood, future studies must confirm that these cells are successfully penetrating the dense, fibrous microenvironment of the pancreas to reach the cysts.[1][2]

The success of mKRAS-VAX paves the way for larger, randomized Phase 2 trials. If the efficacy holds, the implications extend far beyond the pancreas, as KRAS mutations also drive massive proportions of colorectal and non-small cell lung cancers.[2][7]

For now, the data provides a vital proof-of-principle: the immune system can be preemptively armed against one of oncology's most ruthless drivers, offering the first real hope of intercepting pancreatic cancer before the clock runs out.[3][6]